The Study On In Vivo Biocompatibility & Biodistribution Of Several Nanoscale Materials

Biocompatibility evaluation of nano-biomaterials is the key step to enter clinical study. This paper was evaluating the in vivo biocompatibility and biodistribution of Au, Au-Au₂S, and gelatin-siloxane nanoparticles. The results were as follows:1. We confirmed that 100μmol Au of different size and different shapes induced no immune or inflammatory response. The biodistribution, which as a close relationship with the time, the size and the shape, showed that the Au mainly deposited in reticuloendothelial system (RES) such as liver and spleen.2. The Au-Au₂S NPs were successfully synthesized. It had good biocompatibility proved by hemolysis experiments, acute systemic toxicity, biochemical experiments, pathological testing and TEM. 87% of NPs were cleaned from the blood in a minute and the main deposited organs were the liver and spleen Cisplatin-loaded NPs showed no significant difference of biodistribution in healthy mice. The methods of injection were a great influence on biodistribution in tumor-bearing mice: it was small in tumor by tail vein injection, while had a good enhanced penetration and retention effect by intra-tumor injection. Hence it was a potential in situ vaccination or passive targeted drug delivery carrier.3. The gelatin-siloxane and gelatin-siloxane-Tat NPs were successfully synthesized. Both NPs had good biocompatibility which was confirmed by hemolysis experiments, acute systemic toxicity, chronic toxicity, biochemical experiments and pathological examination. The study of biodistribution and fluorescence photographs of frozen sections showed that Gelatin-siloxane NPs mainly deposited in the liver, spleen, lungs and kidneys; however, gelatin-siloxane-Tat NPs were not only in the liver, spleen, lungs and kidneys but also in the heart, brain, muscle and large intestine. Thus, the gelatin-siloxane NPs were potential gene vectors.